Skip to main content

Advertisement

Table 1 General characteristics of the population included in the study (n = 553)

From: Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients

  N. patients (%) Non-STR (n = 457) STR (n = 96) P value
Baseline calendar year     
  19992003 187 (33.8) 187 (40.9) /  
  20042007 181 (32.7) 181 (39.6) /  
   2008-2012 185 (33.5) 89 (48.1) 96 (100.0)  
Age, years a 39 (33–45) 38 (33–45) 42 (32–47) 0.06
Male gender 391 (70.7) 324 (70.9) 67 (69.8) 0.83
Non-Italian nationality 130 (23.0) 103 (23.4) 27 (28.1) 0.24
Injecting drug use (as risk factor) 93 (11.4) 57 (12.5) 6 (6.3) 0.08
CDC class C 130 (23.5) 109 (23.9) 21 (21.9) 0.68
Years from HIV diagnosis a 2.6 (0.7-7.4) 2.5 (0.5-7.4) 3.0 (1.4-7.6) 0.09
Naïve 283 (51.2) 248 (54.3) 35 (36.5) 0.002
Number of treatment lines at EFV start a,c 2 (2–3) 3 (2–3) 2 (2–3) 0.17
Baseline Viral Load, log copies/mL a,b 4.8 (4.6-5.2) 4.8 (4.6-5.3) 4.8 (4.1-5.3) 0.35
Nadir CD4 cells count, cells/μL a 196 (93–262) 180 (91–248) 246 (121–326) 0.1
Baseline CD4 cells count, cells/μL a 300 (207–437) 275 (185–433) 430 (322–573) 0.55
Co-administered NRTIs:     
  TDF + FTC/3TC 315 (57.0) 219 (47.9) 96 (100.0)  
  ABC + 3TC 21 (3.8) 21 (4.6) /  
  AZT + 3TC 130 (23.5) 130 (28.5) /  
  Other 87 (15.7) 87 (19.0) /  
  1. Notes: values are expressed as number (percentage), except for amedian (interquartile range); bnaïve patients; cexperienced patients. Bold values are statistically significant p values.
  2. Abbreviations: BID twice daily, OD once daily, STR single tablet regimens, EFV efavirenz, NRTIs nucleoside reverse transcriptase inhibitors, TDF tenofovir, FTC emtricitabine, 3TC lamivudine, ABC abacavir, AZT zidovudine: D4T, stavudine.